Plasma Polyethylene Glycol (PEG) Levels Reach Steady State Following Repeated Treatment with N8-GP (Turoctocog Alfa Pegol; Esperoct®)
Abstract Background Extended half-life (EHL) factor VIII (FVIII)-replacement therapies enable patients with haemophilia A to maintain higher activity levels with fewer injections. N8-GP (turoctocog alfa pegol; Esperoct®) is an EHL product derived from conjugation of polyethylene glycol (PEG) to a re...
| Главные авторы: | , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
Adis, Springer Healthcare
2020-03-01
|
| Серии: | Drugs in R&D |
| Online-ссылка: | https://doi.org/10.1007/s40268-020-00297-1 |